BGI
SYRE icon

B Group Inc’s Spyre Therapeutics SYRE Stock Holding History

B Group Inc’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.21M Sell
70,000
-30,000
-30% -$2.19M 2.92% 13
2026
Q1 		$5.04M Hold
100,000
– – 3.74% 10
2025
Q4 		$3.28M Hold
100,000
– – 2.42% 11
2025
Q3 		$1.68M Buy
100,000
+20,000
+25% +$326K 1.23% 14
2025
Q2 		$1.2M Buy
80,000
+10,000
+14% +$148K 0.92% 16
2025
Q1 		$1.13M Buy
70,000
+20,000
+40% +$416K 0.97% 14
2024
Q4 		$1.16M Buy
+50,000
New +$1.47M 0.71% 12

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

B Group Inc's SYRE Position: Q2 2026 in Review

B Group Inc reduced its Spyre Therapeutics (SYRE) stake by 30% in Q2 2026, selling an estimated $2.19M and leaving 70,000 shares worth $6.21M. The position accounts for 2.92% of the portfolio, ranked #13.

B Group Inc first reported a position in SYRE in Q4 2024 and has held it in 7 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • B Group Inc held 70,000 shares of Spyre Therapeutics worth $6.21M as of Q2 2026.
  • B Group Inc sold 30,000 Spyre Therapeutics shares in Q2 2026, an estimated $2.19M.
  • Spyre Therapeutics made up 2.92% of B Group Inc's portfolio in Q2 2026, its #13 holding.
  • B Group Inc first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on B Group Inc's 13F filing for Q2 2026, filed 14 Aug 2026.